Pomerantz Law Firm Files Class Action Against PepGen Inc. Over Securities Violations

Overview The Pomerantz Law Firm has officially filed a class action lawsuit against PepGen Inc. and certain of its executives, reflecting serious allegations of federal securities law violations. This action is significant for investors who acquired PepGen securities between March 7, 2024, and March 3, 2025. The lawsuit, situated in the United States District Court for the Eastern District of New York, aims to hold the company accountable for its alleged misleading statements about its promising drug, PGN-EDO51. ## Details of the Lawsuit Under docket number 25-cv-03221, the lawsuit represents all individuals and entities that purchased PepGen securities during the specified period, who are seeking damages for what they believe are harmful effects of the company's failure to disclose accurate information. Lead Plaintiff applications will be accepted until August 8, 2025, urging interested investors to step forward. More information about the lawsuit and how to participate can be found at Pomerantz Law Firm's site. ## Background on PepGen Founded to address severe neuromuscular and neurological conditions, PepGen is a biotechnology firm that focuses on oligonucleotide therapies. Its lead candidate, PGN-EDO51, was initially projected to provide hope for patients with Duchenne muscular dystrophy (DMD), a rare genetic disorder leading to muscle degeneration. DMD results from a mutation in the dystrophin gene, which severely hampers the production of the dystrophin protein needed for muscle function. PGN-EDO51 was designed to skip exon 51 of the dystrophin transcript, a strategy targeting about 13% of DMD patients for the potential production of a functional dystrophin protein. PepGen was conducting two pivotal Phase 2 trials—CONNECT1-EDO51 and CONNECT2-EDO51—to test the efficacy of PGN-EDO51. However, allegations suggest that during the Class Period, executives consistently presented overly optimistic claims regarding the drug's prospects and clinical outcomes. ## Allegations of Wrongdoing The lawsuit contends that the defendants misled investors through false and misleading statements. For instance, they allegedly did not disclose critical information indicating that PGN-EDO51 was not as effective or as safe as promoted. Reports from September 2024 highlighted disappointing clinical trial results, marking a significant deviation from the company's assertions. A press release from PepGen in July 2024 detailed